This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Artificial intelligence (AI) has revolutionised many industries, yet its adoption in pharmaceutical drugdevelopment has been notably slower. For years, AI and machine learning (ML) were often dismissed as little more than advanced statistics with little practical value in drugdevelopment.
Data science has emerged as an innovative tool in the biopharmaceutical industry, leveraging the power of machine learning and artificial intelligence to drive innovation and efficiency across the entire drugdevelopment lifecycle. These complex molecules require precise engineering to ensure optimal efficacy and safety.
Once a patient develops advanced cirrhosis/end-stage liver disease there are no specific therapies to significantly avoid major decompensations and death in the next few years. Could you describe the platform of macrophage biology and cell engineering used by Resolution Therapeutics in developing their cell therapies?
Phenomix Sciences , led by CEO Mark Bagnall, is using precision medicine to make treatments more targeted and effective. In this interview, Bagnall explains how this approach is improving patient outcomes and driving the development of better obesity drugs.
Tom Ireland writes about the companies and technologies that are reimagining phage therapy. Soon after its publication, scientists, journalists, and investors were revisiting ‘phage therapy’ as a promising alternative to our failing antibiotics. Nearly three million drug-resistant infections occur annually in the U.S.
Drugdevelopment is challenging, including not only the complexities of biomolecular drug mechanisms but also the convolutions of regulatory pathways and commercialization strategies. This includes funding large-scale clinical trials and establishing robust manufacturing/distribution networks.
In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. This intersection is where pharmacognosy meets drug patents, creating a unique landscape that shapes the future of medicine.
As a result, drugdevelopers make better decisions more quickly (removing 50% of study timeline whitespace) to bring new therapies to market faster. Accelerate customer speed to market With a modern and integrated user experience, AI solutions put the right data and insights into the right hands in real time.
Contrary to popular belief, ageing is not caused by just random wear and tear of our bodies over time but is instead caused by a discrete set of biological mechanisms that we now better understand and can target with therapies. a clinical-stage private biopharma company developingtherapies for neurological and psychiatric diseases.
Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists -- so far.
But commitment to neuroscience drugdevelopment is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. Historically, what has limited investor interest in funding neurological and psychiatric therapies in development?
2 Unmet needs in lung cancer treatment Recent decades have seen significant advancements in lung cancer treatment, especially with the introduction of targeted therapies and immunotherapies, which have notably improved survival rates. 7 Recent clinical studies highlight promising developments in c-MET-targeting ADCs for NSCLC.
Moreover, scaffolding inhibitors demonstrated no deleterious effects on effector T cell functions or T-regulatory cell numbers, which we believe enables potential combination with CAR-T or T-cell engagers without any negative effects on those immune therapies.
For more insights, refer to Part 1 of this series, where we explore foundational concepts for early drug discovery workflows. About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries.
Although effective drugs and therapies have been developed for most breast cancer subtypes, triple negative breast cancer lacks the key receptors that these drugs interact with – in other words, it’s negative for the three receptors for which […]
The mission of Lineage Cell Therapeutics is to deliver on some of the early promises of cell therapy. Cell therapy as a concept is a wonderful idea, but many of the early efforts never generated the kind of clinical data that gets people excited and leads to new medicines. In some cases, cell therapy can be curative for the patient.
Dr Pooja Hingorani, Senior Medical Director of Oncology Early Development at AbbVie , shares her journey in STEM, from her early days in New Delhi to her impactful career in oncology research and drugdevelopment. I opted for medicine due to my love for biological sciences.
The pharmaceutical industry is undergoing a major shift towards the development of breakthrough medicines and advanced therapies. This continued innovation highlights the complexity of the drugdevelopment process, particularly as the field is highly regulated by health authorities around the world.
Five Promising Treatment Areas in Early-Phase DrugDevelopment in 2024 aasimakopoulos Wed, 04/17/2024 - 15:52 Early-phase drugdevelopment is an ever-changing landscape, as emerging science leads to new promising areas of research for the treatment of human health issues.
About the authors Dr Raminderpal Singh Dr Raminderpal Singh is a recognised visionary in the implementation of AI across technology and science-focused industries. This iterative nature of scientific investigation often leads to new discoveries as researchers refine their understanding of the data.
Advances in predictive modeling, high-throughput screening, and omics technologies have provided powerful tools to uncover safety risks early in the drugdevelopment pipeline. Historically, many drug candidates have been discontinued during late-stage clinical trials due to unforeseen toxicities.
Antibody-drugconjugates (ADCs) represent a significant advancement in drug discovery, combining the precision of monoclonal antibodies with the cancer-killing power of cytotoxic drugs. Wangs research focuses on developing mechanistic mathematical models to quantitatively characterise ADC-induced toxicities.
Top 10 Life Science Resources for Summer 2024 pmjackson Thu, 07/25/2024 - 14:44 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for your convenience. Tags Science and Health Weight 16 Read the eBook.
The science behind drug formulation The formulation of a drug is both an art and a science, requiring a deep understanding of the drug’s chemical and physical properties. 1 Challenges in drug formulation Developing a successful drug formulation is fraught with challenges.
Top 10 Life Science Resources pmjackson Mon, 10/30/2023 - 16:16 There’s a lot of life science content out there, which is why we’ve curated a selection of our expert insights, tips, case studies, and scientific and regulatory information for you. Catch up on what you may have missed below! The Altascientist : Issue No. Watch the video.
Organoid technologies are becoming an invaluable solution for preclinical research, with the ability to augment the development of personalised medicine, drug discovery and gene therapies. 5 Organoids are recognised as New Alternative Methods (NAMs) in drugdevelopment.
Science, 2020. With so much information swirling around these days about the coronavirus disease 2019 (COVID-19) pandemic, it would be easy to miss one of the most interesting and significant basic science reports of the past few weeks. Credit: Adapted from Yan R., Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. 27 March 2020.
My Attendance at the 2024 Boston Society Cell and Gene Therapy Conference pmjackson Tue, 06/11/2024 - 20:49 , via Wikimedia Commons" data-entity-type="file" data-entity-uuid="c7a7fa8b-b2fe-4d84-a75e-d1ba3a4e2caf" src="[link] width="742" height="249" loading="lazy" /> Ecm85, CC BY-SA 3.0
aimed at identifying and characterizing the challenges in developingtherapies for ultra-rare diseases and conditions that affect exceedingly small populations. By Sarah Wicks — On May 21, 2024, the EveryLife Foundation for Rare Diseases (ELF) will host a Scientific Workshop at the National Press Club in Washington, D.C.
Diabetes and cardiac fibrosis are two conditions in dire need of new therapies,” said Todd Golub, director of the Broad Institute. For both patient populations, there are no safe and effective therapies for reversing disease. He is also an institute member and director of the Cardiovascular Disease Initiative at the Broad.
Altasciences’ Commitment to Supporting Pharma and Biotech With Comprehensive Bioanalytical Services pmjackson Wed, 11/13/2024 - 14:50 Greater Montréal, Québec, 11/13, 2024 — Altasciences , a trusted drugdevelopment research partner for over 30 years, continues its commitment to providing world-class bioanalytical services.
As we continue to evolve our drug characterisation processes at Verseon, we see the extensive use of assembloids as essential enabling technology for the future of all drugdevelopment. 22-26 Technically, these findings could apply to both restoration and enhancement of organ function. 2017;23(1):49-59. 2019;363(6423):126-7.
Thanks to its capability to recruit the natural protein degradation system of a cell, PROTACs (PROteolysis TArgeting Chimera) appears as a very promising technology in cancer therapy and disease treatment.
From a very young age, I was drawn to science and medicine. This early exposure to bench science had a long-lasting impact. Through further research and work as a principal investigator on clinical studies for several central nervous system indications, I laid the groundwork for a career in gene therapydrugdevelopment.
With a highly skilled team of Salesforce consultants and developers with Healthcare and Life Sciences (HLS) experience, Perficient is especially interested in this year’s announcements for the vertical. Here are takeaways for Salesforce clients, consultants, and developers working in HLS.
Rapid growth in gene therapy is expected to receive additional support as the Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) prepares to launch Operation Warp Speed for Rare Diseases. Peter Marks, head of FDA’s CBER – the organization responsible for regulating gene therapies.
While these approaches often produce encouraging initial results, the development of drug resistance remains a major obstacle for long-term patient survival. Most targeted cancer therapies used today operate by inhibiting targets along well-known oncogenic signalling cascades.
Now a new study published in the journal Science Advances [1] demonstrates the promise of wearables also extends to the laboratory. A team of engineers has developed a flexible, adhesive strip that, at first glance, looks like a Band-Aid. It can provide continuous monitoring, for weeks, months, or over the course of study. •
An Opportunity to Leverage the Newly Created Rare Disease Advisory Committee across CDER and CBER In Frank and James’ 2018 proposal there was also a recommendation for the formation of a Rare Disease Advisory Committee, which would allow FDA access to experts in the science of small trials and other aspects of rare disease research.
. “Pfizer’s goal with AWS is to expedite the processes for drug discovery and development in ways that can ultimately enhance patient experiences and deliver new therapies to market. Pfizer has an extensive collection of documents that contain valuable data from a variety of drugdevelopment processes.
Read the Guide FDA Launches Pilot Program to Help Further Accelerate Development of Rare Disease Therapies One frustrating aspect of traditional drugdevelopment, especially for rare disease communities, is the tempo of regulatory decisions on potential drugs.
I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. It was then that I knew I wanted to dedicate my career to science. If you are passionate about science and technology GO FOR IT! BECOME A ROLE MODEL!
Today these medicines, called targeted therapies, are available for treating many forms of cancer. Targeted therapies took center stage when Alice Shaw started her career as a physician-scientist caring for patients with lung cancer. Clinical trial investigators are the eyes and ears in the clinic for pharmaceutical drugdevelopers.
Despite a rapidly evolving clinical development landscape, we’ve remained grounded in medicine and science, helping sponsors achieve their clinical development goals across a range of therapeutic areas through our ability to adapt to changing client needs, deliver customized study teams, and dedicated scientific expertise.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content